OWKIN

AI Diagnostics for Pharma

Next-generation AI Dx

↳ Matching drugs to patients in clinical trials and in clinical routine

AI diagnostics unlock significant value for pharma

Dx are crucial for oncology drug success, but existing Dx struggle to keep up:



Cost per patient rising

Cost per patient has risen by $45K in 5 years.[1]



Low probability of trial success

Only 10% of oncology drugs reach the market.[2]

30% revenue loss

From missed testing opportunities.[3]

Owkin Dx improve diagnosis in clinical trials and clinical routine

Work with Owkin to develop de-novo biomarker Dx or to integrate one of Owkin's existing products.

Clinical trials		Clinical routine
Pharma need	Pharma need	Pharma need
Accelerate trial recruitment RUO*	**Increase the likelihood of trial succeeding through better characterization of the patients responding to drug**	**Find the right patients for drug to maximise the revenue potential**
↓	↓	↓
Owkin solution	Owkin solution	Owkin solution
AI-biomarker screening tool to optimize recruitment RUO*	**AI digital-pathology Dx/CDx to match patients to drugs, first in clinical trial and later in clinical routine** RUO IUO IVD	**AI Dx to find the right patients for your drug from routine H&E slides** IVD

*Certain products are labeled Research Use Only (RUO) or IVD for Performance Study Only (PSO) based on regional regulatory requirements.

Next-generation AI diagnostics

Why work with Owkin to match drugs to patients in clinical trials and clinical routine?

Unrivaled access to patient data

Fast, seamless access to a vast academic data network, providing high-quality patient data for training, testing, and validation in real-world settings.

Cutting-edge AI & scientific innovation

Harness the power of advanced AI techniques, including representation learning, transfer learning, and foundation models, for best-in-class generalizable solutions.

Regulatory and product expertise

Navigate complex regulatory landscapes with confidence, supported by our proven expertise and CE-IVD-approved diagnostic products.

Extensive commercial reach

A strong network of distribution partners to ensure broad market coverage.

Benefit from 'generalizable by design' platform-agnostic solutions.

Trusted by pharma

We are delivering value for our pharma partners

AstraZeneca

Challenge

gBRCA not routinely tested in all breast cancers.

Partnership

Astrazeneca and Owkin partner to develop an AI gBRCA screening solution for breast cancer.

MSD

Challenge

MSI not routinely tested in all cancers.

Partnership

MSD and Owkin partner to develop a biomarker screening tool to improve testing rates for MSI-H in endometrial, gastric, small intestinal and biliary cancers.

Get closer to our science

nature medicine

nature communications

Scan the QR to discover our scientific publications:

(1) Clinical development success rates 2011-2021: Statista 2023, 8% vs 16% phase 1 to approval success rate

(2) Thomas, D. W., Burns, J., Audette, J., Carroll, A., Dow-Hygelund, C., & Hay, M. (2016). Clinical Development Success Rates 2006–2015

(3) American Society of Clinical Oncology (ASCO). (2022). Biomarker Tests in Cancer Care Brief. Retrieved from ASCO.Association of Community Cancer Centers (ACCC). (2023, December 12). The Cost of Biomarker Testing: Moving from Support-Based to Sustainable Solutions. Retrieved from ACCC Buzz.

Get in touch with us at owkin.com/contact

OWKIN.COM